- Oral presentation
- Open Access
- Published:
Can Vaccine-induced Mucosal High Avidity CD8+ CTL Delay AIDS-viral Dissemination from Mucosa?
Retrovirology volume 2, Article number: S100 (2005)
Natural HIV transmission occurs through mucosa, but it is debated whether mucosal cytotoxic T lymphocytes (CTL) can prevent or reduce dissemination from the initial mucosal site to the systemic circulation. Also, the role of CTL avidity in mucosal AIDS viral transmission is unknown. To address these questions, we used delay in acute-phase peak viremia after intrarectal challenge as an indicator of systemic dissemination. We find that a peptide-prime/poxviral boost vaccine inducing high levels of high avidity mucosal CTL can impact dissemination of intrarectally administered pathogenic SHIV-ku2 in macaques, and that such protection correlates better with mucosal than with systemic CTL and particularly with levels of high avidity mucosal CTL.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution License ( https://creativecommons.org/licenses/by/2.0 ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
About this article
Cite this article
Belyakov, I.M., Kuznetsov, V.A., Kelsall, B. et al. Can Vaccine-induced Mucosal High Avidity CD8+ CTL Delay AIDS-viral Dissemination from Mucosa?. Retrovirology 2 (Suppl 1), S100 (2005). https://doi.org/10.1186/1742-4690-2-S1-S100
Published:
DOI: https://doi.org/10.1186/1742-4690-2-S1-S100
Keywords
- Infectious Disease
- Cancer Research
- Systemic Circulation
- Systemic Dissemination
- Viral Transmission